SUMMARY Celiprolol (400 mg) and atenolol (100 mg) were given once a day to 16 patients with stable angina pectoris in a double blind placebo controlled crossover study. Celiprolol produced less suppression of heart rate both at rest and during exercise than atenolol. Both drugs were equally effective in reducing the frequency of angina and in delaying the onset of ischaemia during exercise. Radionuclide ventriculography showed that atenolol but not celiprolol lowered cardiac output at rest and during exercise.
The notable success of ,B adrenoceptor antagonists in the treatment of myocardial ischaemia in patients with coronary heart disease reflects the fact that effort is the main stimulus to the development of such ischaemia. There are some disadvantages associated with the principal therapeutic action of ,B blockade, which is suppression of the increase in heart rate and contractility that normally accompanies exercise.'
These include an increase in left ventricular volume, which is energy wasting, and a reduction in cardiac output during exercise. Thus the interest in ,B blockers with ancillary properties that confer a more favourable haemodynamic profile while retaining the beneficial effect on myocardial ischaemia.
Celiprolol is a new 1, selective adrenoceptor antagonist with partial agonist effects at the 1)2 receptor and direct vasodilating activity. It is orally active, undergoes minimal hepatic metabolism, and is active for at least 24 hours when given in a dose of 400 mg.'
We compared the effects of a daily dose of celiprolol (400 mg) with that of atenolol (100 mg) on angina frequency, effort capacity, and indices of myocardial ischaemia and function at rest and during dynamic exercise in a double blind randomised crossover study of 16 resting heart rate but did suppress heart rate as exercise progressed. Even at peak exercise, however, heart rate was significantly higher on celiprolol than on atenolol (120 (4) beats per minute vs 105 (4) beats per minute, p < 0 005).
The rise in systolic pressure on both drugs was lower than that on placebo, but there were no significant differences between the two drugs ( fig 2) . EXERCISE McLenachan, Wilson, Dargie The low frequency of side effects may reflect the fact that most of the patients had been treated with, and were tolerant of, P blockers before they joined the study.
Discussion
The major therapeutic action of conventional ,B blockers in angina pectoris is the suppression of exercise induced tachycardia, which leads to a reduction in myocardial oxygen requirement. P Blockers with intrinsic sympathomimetic activity produce less of a reduction in heart rate at rest and during exercise but may be less effective antianginal agents than # blockers without this property.3 Figure 1 shows that celiprolol acts like a ,B blocker with intrinsic sympathomimetic activity; it had little effect on resting heart rate but produced considerable blunting of the exercise induced rise in heart rate. At peak exercise, heart rate and double product were significantly higher on celiprolol than on atenolol, yet both drugs were equally effective at reducing myocardial ischaemia during exercise as shown by electrocardiographic indices. Subjective testing showed that both drugs produced an equal reduction in angina frequency in keeping with previous studies that showed the antianginal efficacy of celiprolol.45 There were, however, striking differences in their respective haemodynamic profiles, suggesting different mechanisms of action.
The product of heart rate and systolic blood pressure correlates with oxygen consumption.6 Glyceryl trinitrate relieves angina by lowering the rate-pressure product,7 but if the workload is further increased to raise this product to the baseline level, pain still occurs. The administration of / blockers, however, lowers the rate-pressure product at the onset of ischaemia by about 30%8 suggesting an adverse effect on myocardial oxygen consumption for the same amount of cardiac work at a given pressure.9 Table 3 shows that the rate-pressure product achieved for a similar degree ofmyocardial ischaemia on celiprolol was significantly higher than that on atenolol. The rate-pressure product on both drugs was lower than on placebo. This suggests that the ancillary properties of celiprolol have a beneficial effect on myocardial oxygen balance, either by increasing myocardial oxygen supply or by reducing demand. Several properties of celiprolol may contribute to this effect.
In patients with coronary artery disease drugs with intrinsic sympathomimetic activity produce less of an increase, or even a small fall, in systemic vascular resistance than drugs without such activity.'°Thus the reduction in diastolic blood pressure on celiprolol might be explained by a fall in systemic vascular resistance whereas the reduction on atenolol probably reflects the fall in cardiac output. In addition, celiprolol seems to have a direct vasodilator action since its vasodilator activity is not abolished by blockade of /32 agonist effects by propranolol." Thus a reduction in afterload by intrinsic sympathomimetic activity and vasodilator activity might reduce oxygen demand and improve cardiac pumping in patients with ischaemic heart disease. Furthermore, in animal studies celiprolol had a positive inotropic effect that was not due solely to /32 agonism as this effect also persisted in the presence of propranolol."
Measurement of ejection fraction does not allow us to determine whether an observed rise is caused by increased contractility or to a change in loading conditions. Thus the ability to maintain a higher ejection fraction and cardiac output at a higher heart rate on celiprolol than on atenolol could be explained either by an increase in myocardial contractility or by afterload reduction mediated by both fl2 agonism and direct vasodilator activity. Whether these ancillary actions of celiprolol will be associated with a reduction in side effects of, blockade, particularly fatigue, remains to be seen.
In conclusion, celiprolol is an effective antianginal agent that seems to be well tolerated. It has less effect on heart rate than atenolol and does not reduce cardiac output either at rest or during exercise. These effects are probably related to its ancillary properties including f2 agonism and direct vasodilator activity, which may be beneficial in ischaemic heart disease.
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